These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 27136372)

  • 1. Isoxazole-Based-Scaffold Inhibitors Targeting Cyclooxygenases (COXs).
    Perrone MG; Vitale P; Panella A; Ferorelli S; Contino M; Lavecchia A; Scilimati A
    ChemMedChem; 2016 Jun; 11(11):1172-87. PubMed ID: 27136372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis, pharmacological characterization, and docking analysis of a novel family of diarylisoxazoles as highly selective cyclooxygenase-1 (COX-1) inhibitors.
    Vitale P; Tacconelli S; Perrone MG; Malerba P; Simone L; Scilimati A; Lavecchia A; Dovizio M; Marcantoni E; Bruno A; Patrignani P
    J Med Chem; 2013 Jun; 56(11):4277-99. PubMed ID: 23651359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An attempt to chemically state the cross-talk between monomers of COX homodimers by double/hybrid inhibitors mofezolac-spacer-mofezolac and mofezolac-spacer-arachidonic acid.
    Perrone MG; Miciaccia M; Vitale P; Ferorelli S; Araújo CDCB; de Almeida GS; Souza Domingos TF; da Silva LCRP; de Pádula M; Cabral LM; Sathler PC; Bonaccorso C; Fortuna CG; Scilimati A
    Eur J Med Chem; 2021 Jan; 209():112919. PubMed ID: 33129592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diarylheterocycle core ring features effect in selective COX-1 inhibition.
    Perrone MG; Vitale P; Malerba P; Altomare A; Rizzi R; Lavecchia A; Di Giovanni C; Novellino E; Scilimati A
    ChemMedChem; 2012 Apr; 7(4):629-41. PubMed ID: 22278975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural basis for selective inhibition of Cyclooxygenase-1 (COX-1) by diarylisoxazoles mofezolac and 3-(5-chlorofuran-2-yl)-5-methyl-4-phenylisoxazole (P6).
    Cingolani G; Panella A; Perrone MG; Vitale P; Di Mauro G; Fortuna CG; Armen RS; Ferorelli S; Smith WL; Scilimati A
    Eur J Med Chem; 2017 Sep; 138():661-668. PubMed ID: 28710965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Indole based cyclooxygenase inhibitors: synthesis, biological evaluation, docking and NMR screening.
    Estevão MS; Carvalho LC; Freitas M; Gomes A; Viegas A; Manso J; Erhardt S; Fernandes E; Cabrita EJ; Marques MM
    Eur J Med Chem; 2012 Aug; 54():823-33. PubMed ID: 22796043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thiazole derivatives as inhibitors of cyclooxygenases in vitro and in vivo.
    El-Achkar GA; Jouni M; Mrad MF; Hirz T; El Hachem N; Khalaf A; Hammoud S; Fayyad-Kazan H; Eid AA; Badran B; Merhi RA; Hachem A; Hamade E; Habib A
    Eur J Pharmacol; 2015 Mar; 750():66-73. PubMed ID: 25617797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective COX-1 inhibition as a target of theranostic novel diarylisoxazoles.
    Vitale P; Perrone MG; Malerba P; Lavecchia A; Scilimati A
    Eur J Med Chem; 2014 Mar; 74():606-18. PubMed ID: 24531199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Translational impact of novel widely pharmacological characterized mofezolac-derived COX-1 inhibitors combined with bortezomib on human multiple myeloma cell lines viability.
    Pati ML; Vitale P; Ferorelli S; Iaselli M; Miciaccia M; Boccarelli A; Di Mauro GD; Fortuna CG; Souza Domingos TF; Rodrigues Pereira da Silva LC; de Pádula M; Cabral LM; Sathler PC; Vacca A; Scilimati A; Perrone MG
    Eur J Med Chem; 2019 Feb; 164():59-76. PubMed ID: 30590258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and evaluation of dithiolethiones as novel cyclooxygenase inhibitors.
    Zanatta SD; Manallack DT; Jarrott B; Williams SJ
    Bioorg Med Chem Lett; 2009 Jan; 19(2):459-61. PubMed ID: 19056264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A further pocket or conformational plasticity by mapping COX-1 catalytic site through modified-mofezolac structure-inhibitory activity relationships and their antiplatelet behavior.
    Solidoro R; Miciaccia M; Bonaccorso C; Fortuna CG; Armenise D; Centonze A; Ferorelli S; Vitale P; Rodrigues P; Guimarães R; de Oliveira A; da Paz M; Rangel L; Sathler PC; Altomare A; Perrone MG; Scilimati A
    Eur J Med Chem; 2024 Feb; 266():116135. PubMed ID: 38219659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Syntheses and characterization of nimesulide derivatives for dual enzyme inhibitors of both cyclooxygenase-1/2 and 5-lipoxygenase.
    Li Y; Chen SH; Ou TM; Tan JH; Li D; Gu LQ; Huang ZS
    Bioorg Med Chem; 2011 Mar; 19(6):2074-83. PubMed ID: 21349729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting COX-1 by mofezolac-based fluorescent probes for ovarian cancer detection.
    Scilimati A; Ferorelli S; Iaselli MC; Miciaccia M; Pati ML; Fortuna CG; Aleem AM; Marnett LJ; Perrone MG
    Eur J Med Chem; 2019 Oct; 179():16-25. PubMed ID: 31229884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design of novel N-phenylnicotinamides as selective cyclooxygenase-1 inhibitors.
    Shi L; Li ZL; Yang Y; Zhu ZW; Zhu HL
    Bioorg Med Chem Lett; 2011 Jan; 21(1):121-4. PubMed ID: 21144750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. General role of the amino and methylsulfamoyl groups in selective cyclooxygenase(COX)-1 inhibition by 1,4-diaryl-1,2,3-triazoles and validation of a predictive pharmacometric PLS model.
    Perrone MG; Vitale P; Panella A; Fortuna CG; Scilimati A
    Eur J Med Chem; 2015 Apr; 94():252-64. PubMed ID: 25768707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel quinoline incorporating 1,2,4-triazole/oxime hybrids: Synthesis, molecular docking, anti-inflammatory, COX inhibition, ulceroginicity and histopathological investigations.
    Mohassab AM; Hassan HA; Abdelhamid D; Abdel-Aziz M; Dalby KN; Kaoud TS
    Bioorg Chem; 2017 Dec; 75():242-259. PubMed ID: 29032325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploration of isoxazole analogs: Synthesis, COX inhibition, anticancer screening, 3D multicellular tumor spheroids, and molecular modeling.
    Hawash M; Abdallah S; Abudayyak M; Melhem Y; Abu Shamat M; Aghbar M; Çapan I; Abualhasan M; Kumar A; Kamiński M; Góral T; Dominiak PM; Sobuh S
    Eur J Med Chem; 2024 May; 271():116397. PubMed ID: 38626522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual evaluation of some novel 2-amino-substituted coumarinylthiazoles as anti-inflammatory-antimicrobial agents and their docking studies with COX-1/COX-2 active sites.
    Chandak N; Kumar P; Kaushik P; Varshney P; Sharma C; Kaushik D; Jain S; Aneja KR; Sharma PK
    J Enzyme Inhib Med Chem; 2014 Aug; 29(4):476-84. PubMed ID: 23777557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Docking of Bioactive Compounds Against BRCA and COX Proteins.
    Prog Drug Res; 2016; 71():181-3. PubMed ID: 26939289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis of new 4-phenylpyrimidine-2(1H)-thiones and their potency to inhibit COX-1 and COX-2.
    Seebacher W; Faist J; Presser A; Weis R; Saf R; Kaserer T; Temml V; Schuster D; Ortmann S; Otto N; Bauer R
    Eur J Med Chem; 2015 Aug; 101():552-9. PubMed ID: 26197159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.